Sign up for our upcoming events >>
Home
About
Learn
Advocate
Connect
Resources
More
Alpha PRRT with Pb-212 (all NET)
Lu-177 DOTATATE + Cabozantanib (all NET)
Lu-177 DOTATATE vs Everolimus in Lung NETs
Â
Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs
CABINET Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced NETs After Progression on Prior Therapy
Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs)